Literature DB >> 16246972

Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.

Zhenlong Chen1, Fulong Tan, Ervin G Erdös, Peter A Deddish.   

Abstract

We measured the cleavage of angiotensin I (Ang I) metabolites by angiotensin I-converting enzyme (ACE) in cultured cells and examined how they augment actions of bradykinin B2 receptor agonists. Monolayers of Chinese hamster ovary cells transfected to stably express human ACE and bradykinin B2 receptors coupled to green fluorescent protein (B2GFP) or to express only coupled B2GFP receptors. We used 2 ACE-resistant bradykinin analogues to activate the B2 receptors. We used high-performance liquid chromatography to analyze the peptides cleaved by ACE on cell monolayers and found that Ang 1-9 was hydrolyzed 18x slower than Ang I and &30% slower than Ang 1-7. Ang 1-7 was cleaved to Ang 1-5. Although micromol/L concentrations of slowly cleaved substrates Ang 1-7 and Ang 1-9 inhibit ACE, they resensitize the desensitized B2GFP receptors in nmol/L concentration, independent of ACE inhibition. This is reflected by release of arachidonic acid through a mechanism involving cross-talk between ACE and B2 receptors. When ACE was not expressed, the Ang 1-9, Ang 1-7 peptides were inactive. Inhibitors of protein kinase C-alpha, phosphatases and Tyr-kinase blocked this resensitization activity, but not basal B2 activation by bradykinin. Ang 1-9 and Ang 1-7 enhance bradykinin activity, probably by acting as endogenous allosteric modifiers of the ACE and B2 receptor complex. Consequently, when ACE inhibitors block conversion of Ang I, other enzymes can still release Ang I metabolites to enhance the efficacy of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246972      PMCID: PMC1564276          DOI: 10.1161/01.HYP.0000188905.20884.63

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

1.  Kallikreins when activating bradykinin B2 receptor induce its redistribution on plasma membrane.

Authors:  Claudie Hecquet; Robert P Becker; Fulong Tan; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2002-12       Impact factor: 4.932

2.  Protein kinase Calpha-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement.

Authors:  Michael Holinstat; Dolly Mehta; Tohru Kozasa; Richard D Minshall; Asrar B Malik
Journal:  J Biol Chem       Date:  2003-05-16       Impact factor: 5.157

3.  Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme.

Authors:  Peter V Binevski; Elena A Sizova; Vladimir F Pozdnev; Olga A Kost
Journal:  FEBS Lett       Date:  2003-08-28       Impact factor: 4.124

Review 4.  Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Peptides       Date:  2004-03       Impact factor: 3.750

5.  Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.

Authors:  Gillian I Rice; Daniel A Thomas; Peter J Grant; Anthony J Turner; Nigel M Hooper
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

6.  Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme).

Authors:  H Y Yang; E G Erdös; Y Levin
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

7.  RhoA interaction with inositol 1,4,5-trisphosphate receptor and transient receptor potential channel-1 regulates Ca2+ entry. Role in signaling increased endothelial permeability.

Authors:  Dolly Mehta; Gias U Ahmmed; Biman C Paria; Michael Holinstat; Tatyana Voyno-Yasenetskaya; Chinnaswamy Tiruppathi; Richard D Minshall; Asrar B Malik
Journal:  J Biol Chem       Date:  2003-05-22       Impact factor: 5.157

Review 8.  Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin.

Authors:  Ervin G Erdös; Herbert L Jackman; Viktor Brovkovych; Fulong Tan; Peter A Deddish
Journal:  J Mol Cell Cardiol       Date:  2002-12       Impact factor: 5.000

9.  Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.

Authors:  Dimitris Georgiadis; Fabrice Beau; Bertrand Czarny; Joël Cotton; Athanasios Yiotakis; Vincent Dive
Journal:  Circ Res       Date:  2003-06-12       Impact factor: 17.367

Review 10.  ACE2: from vasopeptidase to SARS virus receptor.

Authors:  Anthony J Turner; Julian A Hiscox; Nigel M Hooper
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

View more
  8 in total

Review 1.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

2.  Kallikrein activates bradykinin B2 receptors in absence of kininogen.

Authors:  Dauren Biyashev; Fulong Tan; Zhenlong Chen; Kai Zhang; Peter A Deddish; Ervin G Erdös; Claudie Hecquet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

3.  Human ACE and bradykinin B2 receptors form a complex at the plasma membrane.

Authors:  Zhenlong Chen; Peter A Deddish; Richard D Minshall; Robert P Becker; Ervin G Erdös; Fulong Tan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

4.  Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling.

Authors:  María Paz Ocaranza; Jorge E Jalil
Journal:  Int J Hypertens       Date:  2012-01-19       Impact factor: 2.420

Review 5.  Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.

Authors:  Manuele Figueiredo da Silva; João Xavier de Araújo-Júnior; Edeildo Ferreira da Silva-Júnior; Luana Heimfarth; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-28       Impact factor: 3.000

6.  The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome.

Authors:  Marite Punapart; Kadri Seppa; Toomas Jagomäe; Mailis Liiv; Riin Reimets; Silvia Kirillov; Allen Kaasik; Lieve Moons; Lies De Groef; Anton Terasmaa; Eero Vasar; Mario Plaas
Journal:  Genes (Basel)       Date:  2021-10-28       Impact factor: 4.096

7.  Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Authors:  Prasad Gunaruwan; Abdul Maher; Lynne Williams; James Sharman; Matthias Schmitt; Ross Campbell; Michael Frenneaux
Journal:  Clin Sci (Lond)       Date:  2009-03       Impact factor: 6.124

8.  A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.

Authors:  Michael R Garvin; Christiane Alvarez; J Izaak Miller; Erica T Prates; Angelica M Walker; B Kirtley Amos; Alan E Mast; Amy Justice; Bruce Aronow; Daniel Jacobson
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.713

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.